Analysis of 18F-AV-1451 PET Imaging in Cognitively Healthy, MCI, and AD Subjects

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

383

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 28, 2017

Study Completion Date

July 28, 2017

Conditions
Alzheimer's Disease
Interventions
DRUG

florbetapir F 18

DRUG

Flortaucipir F18

PROCEDURE

Brain PET Scan

positron emission tomography (PET) scan of the brain

Trial Locations (27)

10016

Center for Brain Health - NYU Langone Medical Center, New York

19104

University of Pennsylvania, Philadelphia

27710

Duke University Medical Center, Durham

32806

Sandlake Imaging, Orlando

33064

Quantum Laboratories, Deerfield Beach

33407

Independent Imaging, West Palm Beach

33613

USF Health Byrd Alzheimer's Center, Tampa

33709

Meridien Research, St. Petersburg

33912

21st Century Oncology, Fort Myers

63110

Center for Clinical Imaging Research, St Louis

85006

Banner Alzheimer's Institute, Phoenix

85258

Four Peaks Neurology, Scottsdale

85259

Mayo Clinic, Scottsdale

85351

Banner Sun Health Research Institute, Sun City

89147

Las Vegas Radiology, Las Vegas

90404

Neurological Research Institute, Santa Monica

92663

Hoag Memorial, Newport Beach

92697

UC Irvine, Irvine

94158

UC San Francisco, San Francisco

95816

Norther California PET Imaging Center, Sacramento

95817

UC Davis, Sacramento

06510

Molecular NeuroImaging, New Haven

02114

Massachusetts General Hospital, Boston

02118

Boston University, Boston

02169

Alzheimer's Disease Center, Quincy

02903

Rhode Island Hospital, Providence

02906

Butler Hospital, Providence

Sponsors
All Listed Sponsors
lead

Avid Radiopharmaceuticals

INDUSTRY